START FORM
Download Start Form - English
Download Start Form - Spanish
Access the E-sign Start Form
Visit Patient Site
Safety Information
Prescribing Information
Request Information
START FORM

E-sign Start Form

Start Form
Visit Patient Site
Safety Info
Prescribing Info
Stay Connected

ABOUT SMA
WHY SPINRAZA?
STARTING SPINRAZA
- How to Start
- Dosing & Administration
PATIENTS ON THERAPY
RESOURCE LIBRARY

E-sign Start Form

START FORM
Download Start Form - English
Download Start Form - Spanish
Access the E-sign Start Form
Visit Patient Site
Safety Information
Prescribing Information
Request Information

Please contact your Rare Disease Account
Executive if you have questions or would like to be
removed from the Treatment Locator Tool.

Let the SMA community know that you
 administer SPINRAZA

*Indicates required field.

Prescribing Physician NPI (this will not be displayed to patients):*

Site of Care Name:*

Site of Care Address Line 1:*

Site of Care Address Line 2:

City:*

*State:

ZIP Code:*

Site of Care Office Phone Number:*

Extension (Optional):

Prescribing Physician First and Last Name:*

*Specialty

Internal Medicine

Primary Care Provider

Interventional Radiologist

Neurologist

Other

Neuromuscular Specialist

*I authorize Biogen to post the above listed information on SPINRAZA.com. I understand I can make any changes to the information at any time via this form, subject to verification by a Biogen representative. I understand that removals must be requested through a Biogen representative. I acknowledge that Biogen is not responsible for reviewing or updating information unless requested, and I confirm that I have read and agree to the Legal Disclaimer and Privacy Policy.

Prescribing Physician Email (this will not be displayed to patients):*

Prescribing Physician Phone Number (this will not be displayed to patients):*

(Optional) Biogen will reach out via the above email and phone number to verify this information. Check this box to provide an alternate point of contact for Biogen verification.

Contact Name or Department:

Contact Email:

Contact Phone Number:

Extension:

(Optional) I authorize Biogen, and companies working with Biogen, to contact me by mobile or online digital media, mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Biogen for marketing, including targeted online marketing, as well as to help develop new products, services, and programs. I understand that Biogen will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Biogen. I understand that I may revoke this authorization and choose not to receive information from Biogen by using the link provided in emails I receive from Biogen, clicking the “Unsubscribe” link at the bottom of this page, sending an email with the subject “Unsubscribe” to privacy@biogen.com or mailing a letter to Biogen, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC, 27709. For more information visit biogen.com/privacy.

Residents of certain US States (including but not limited to California) may have additional rights regarding the collection, use, maintenance, disclosure, and deletion of your personal information. To understand or exercise those rights California residents please visit https://www.biogen.com/privacy-center/californiapolicy.html. For more information, visit https://www.biogen.com/privacy-center.html.

Date:

SMA, spinal muscular atrophy.

INDICATION

SPINRAZA^® (nusinersen) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

SPINRAZA^® (nusinersen) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

SPINRAZA^® (nusinersen) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

Request Information
Sign up with us to receive news and support information and hear about upcoming events.

ABOUT SMA

What Is SMA? How SMA Affects Nerves
and Muscles Multidisciplinary Care

Why SPINRAZA?

About SPINRAZA How SPINRAZA Works Presymptomatic Efficacy Early-Onset Efficacy Later-Onset Efficacy Real-World Evidence Safety

Starting SPINRAZA

How to Start Dosing & Administration

Patients on Therapy

RESOURCE LIBRARY

Access & Reimbursement SMA360°™ Patient Support Events Video Hub Treatment Locator Consent

Cookies
Privacy Policy
Terms and Conditions
Contact Us
Unsubscribe

Cookies
Privacy Policy
Terms and Conditions
Contact Us
Unsubscribe

Let the SMA community know that you administer SPINRAZA

Let the SMA community know that you
 administer SPINRAZA